Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 29, Issue 4, Pages 243-259Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2019.1597850
Keywords
CA-4948; inflammation; interleukin-1 receptor-associated kinase; Myd88; PF-06650833; rheumatoid arthritis; Toll; IL-1R
Categories
Ask authors/readers for more resources
Introduction: Interleukin-1 receptor-associated kinase 4 (IRAK4) is the most upstream kinase in Toll/Interleukin-1 receptor (TIR) signaling. Human and rodent genetics support the role of IRAK4 in immune function and the involvement of IRAK4-dependent signaling in certain cancers is hypothesized. The accumulating evidence has motivated the discovery of IRAK4 inhibitors that could be used therapeutically.Areas covered: This review summarizes patents published in 2016-2018 claiming IRAK4 inhibitors. Representative analogues from each patent are presented with a focus on compounds that have been profiled in cellular and in vivo assays.Expert opinion: The last three years have seen an increased number of IRAK4 inhibitors with which to assess the therapeutic potential of the target. At least 5 companies are believed to have advanced to the clinic. Pfizer is in phase II for rheumatoid arthritis (RA). The outcomes of these studies should inform on the therapeutic potential in autoimmune disease and cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available